NCT06071026

Brief Summary

Net ultra filtration (NUF) is one of the most important parameters during renal replacement therapy (RRT) whose role is to control fluid balance by water removal. To our knowledge, there are no prospective studies or guidelines about the setting of this parameter. In the NEPTUNE study, we aim to compare the hemodynamic effect of three NUF rates during RRT: 1 ml/kg/h, 2 ml/kg/h and 3 ml/kg/h. The research hypothesis is that one of the three flow rates evaluated induces the fewest hemodynamic instabilities related to RRT, while guaranteeing the best possible fluid balance.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
39

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 19, 2023

Completed
17 days until next milestone

First Posted

Study publicly available on registry

October 6, 2023

Completed
Same day until next milestone

Study Start

First participant enrolled

October 6, 2023

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 8, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 8, 2025

Completed
Last Updated

November 17, 2025

Status Verified

July 1, 2025

Enrollment Period

1.8 years

First QC Date

September 19, 2023

Last Update Submit

November 14, 2025

Conditions

Keywords

fluid overloadrenal replacement therapyhemodynamic instabilityacute kidney injury

Outcome Measures

Primary Outcomes (1)

  • Occurrence of HIRRT

    Occurrence of Hemodynamic Instability related to Renal Replacement Therapy

    6 hours

Secondary Outcomes (18)

  • Number of HIRRT

    6 hours

  • Water depletion

    6 hours

  • Fluid intake

    6 hours

  • Time before HIRRT in each session

    6 hours

  • Time between start of RRT and HIRRT

    28 days

  • +13 more secondary outcomes

Study Arms (3)

1 ml/kg/h

EXPERIMENTAL

Net ultra filtration setting: 1 ml/kg/h

Device: Net Ultra Filtration Rate

2 ml/kg/h

EXPERIMENTAL

Net ultra filtration setting: 2 ml/kg/h

Device: Net Ultra Filtration Rate

3 ml/kg/h

EXPERIMENTAL

Net ultra filtration setting: 3 ml/kg/h

Device: Net Ultra Filtration Rate

Interventions

The net ultra filtration rate is modified every 6 hours accordingly to randomisation

1 ml/kg/h2 ml/kg/h3 ml/kg/h

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients hospitalised in the intensive care unit of one of the two participating centres
  • Patients with Kidney Disease: Improving Global Outcomes 3 (KDIGO3) acute kidney injury (AKI) requiring a continuous RRT during their stay in the intensive care unit, regardless of the aetiology of the AKI
  • Need to prescribe water loss by net ultrafiltration (NUF), defined by at least one of the following sub-criteria:
  • weight gain ≥ 1 kg relative to entry weight
  • oligo-anuria ≥ 24 hours
  • clinical impact of fluid overload as judged by the clinician: acute lung oedema clinical or at CT-scan, difficulty of weaning from mechanical ventilation.
  • Hemodynamic stability in the 2 hours preceding the start of NUF, defined by all of the following sub-criteria:
  • absence of vasopressors (noradrenaline) or stability or reduction in their dosage
  • no need for resuscitative fluids as judged by the clinician
  • Patient or his/her trusted support person/legal representative/family member having given free and informed consent, and having signed the consent form or patient included in an emergency situation.
  • Patient affiliated to or benefiting from a health insurance scheme.

You may not qualify if:

  • Patient moribund, with life expectancy too low to benefit from treatment, or with decision to discontinue treatment
  • Patient participating in an another interventional study
  • Patient under court protection or guardianship
  • Patient/trusted person/legal representative/family member for whom it is impossible to give informed information.
  • Pregnant, parturient or breast-feeding patient.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier Universitaire de Nîmes

Nîmes, France

Location

Related Publications (4)

  • Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, Edipidis K, Forni LG, Gomersall CD, Govil D, Honore PM, Joannes-Boyau O, Joannidis M, Korhonen AM, Lavrentieva A, Mehta RL, Palevsky P, Roessler E, Ronco C, Uchino S, Vazquez JA, Vidal Andrade E, Webb S, Kellum JA. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015 Aug;41(8):1411-23. doi: 10.1007/s00134-015-3934-7. Epub 2015 Jul 11.

    PMID: 26162677BACKGROUND
  • Murugan R, Balakumar V, Kerti SJ, Priyanka P, Chang CH, Clermont G, Bellomo R, Palevsky PM, Kellum JA. Net ultrafiltration intensity and mortality in critically ill patients with fluid overload. Crit Care. 2018 Sep 24;22(1):223. doi: 10.1186/s13054-018-2163-1.

    PMID: 30244678BACKGROUND
  • Sharma S, Waikar SS. Intradialytic hypotension in acute kidney injury requiring renal replacement therapy. Semin Dial. 2017 Nov;30(6):553-558. doi: 10.1111/sdi.12630. Epub 2017 Jun 30.

    PMID: 28666082BACKGROUND
  • Murugan R, Kerti SJ, Chang CH, Gallagher M, Neto AS, Clermont G, Ronco C, Palevsky PM, Kellum JA, Bellomo R. Association between Net Ultrafiltration Rate and Renal Recovery among Critically Ill Adults with Acute Kidney Injury Receiving Continuous Renal Replacement Therapy: An Observational Cohort Study. Blood Purif. 2022;51(5):397-409. doi: 10.1159/000517281. Epub 2021 Jul 21.

    PMID: 34289471BACKGROUND

MeSH Terms

Conditions

EdemaAcute Kidney Injury

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and SymptomsRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Officials

  • Saber D. BARBAR, MD, PhD

    Centre Hospitalier Universitaire de Nīmes

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
CROSSOVER
Model Details: Multiple N of one trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 19, 2023

First Posted

October 6, 2023

Study Start

October 6, 2023

Primary Completion

July 8, 2025

Study Completion

July 8, 2025

Last Updated

November 17, 2025

Record last verified: 2025-07

Locations